The review found convergent evidence linking these effects to signaling pathways involving SMAD2/3, BMP2, SIRT1/Nrf2/HO-1, CDK12, RANKL–RANK, NF-κB, MAPK and ERK. Its scope was limited to English-language in vivo and in vitro research available through November 2025; it did not test ellagic acid in people with osteoporosis. The researchers searched PubMed, Scopus, Web of Science and Google Scholar in accordance with PRISMA guidelines.

Eligible investigations assessed the effects of ellagic acid on osteoporosis-related outcomes. Information was extracted about each experimental model, the compound’s dosage and administration, the signaling pathways evaluated and the bone-related results. Thirteen studies met the inclusion criteria.

The evidence came from cell cultures and animal models rather than clinical trials, so the findings describe laboratory activity under experimental conditions rather than established benefits for human bone health. The review’s purpose was to assess the available preclinical evidence and identify molecular pathways associated with ellagic acid’s effects. Ellagic acid enhanced osteoblast differentiation, viability and bone-forming capacity in the included experiments.

It increased osteogenic markers and was associated with activation of SMAD2/3 and BMP2 signaling, as well as the SIRT1/Nrf2/HO-1 pathway. The compound also inhibited CDK12, which the review identified as a negative regulator of osteoblast differentiation. In parallel, ellagic acid reduced osteoclast differentiation and bone resorption.

It disrupted RANKL–RANK interactions and inhibited downstream NF-κB, MAPK and ERK signaling. Together, these results indicate that the compound affected both bone formation and bone breakdown in the reviewed experimental systems. They do not establish that the same balance of effects will occur in patients.

Animal experiments extended these cellular findings to structural and mechanical outcomes. In ovariectomy-induced and microgravity-induced osteoporosis models, ellagic acid administration improved bone mineral density, preserved trabecular microarchitecture and increased mechanical strength. The treated animals also showed attenuation of oxidative stress and inflammatory responses within the bone microenvironment.

These observations are consistent with the review’s interpretation that ellagic acid may protect bone through coordinated effects on formation, resorption and the cellular environment. However, the evidence base consists of controlled preclinical studies rather than human trials. The authors also identified bioavailability as an important challenge for translating the results.

They concluded that large-scale, long-term clinical studies are required to confirm efficacy, determine appropriate dosing strategies and address bioavailability before ellagic acid can be considered an established osteoporosis treatment.

Subject of Research: Preclinical evidence on ellagic acid effects in osteoporosis cell and animal models

Article Title: Ellagic acid and bone health: a systematic review of preclinical studies on its protective role against osteoporosis

Article References: Gholizadeh, M., Sarajar, B. O., Asadi, J., & Soleimani, A. A. (2026). Ellagic acid and bone health: a systematic review of preclinical studies on its protective role against osteoporosis. Molecular Biology Reports, 53(1), Article 1531. https://doi.org/10.1007/s11033-026-12648-3

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12648-3

Keywords: ellagic acid, osteoporosis, systematic review, preclinical studies, bone formation, bone resorption, osteoblasts, osteoclasts, animal models, clinical evidence, Ellagic, acid

The researchers found that excess glucose, alcohol or acetate activated a mitochondrial reactive oxygen species signaling pathway, which engaged the integrated stress response and the transcription factor CEBPB. This signaling increased ACSS1, a protein involved in converting acetate into acetyl-CoA. Once accumulated, ACSS1 raised acetyl-CoA production from supplied acetate or from acetate generated internally from glucose or ethanol.

The metabolic rewiring promoted excessive protein acetylation and specifically inactivated malate enzyme 2 (ME2) through acetylation at lysine 94. ME2 inactivation disturbed the malate-aspartate shuttle and, according to the study, created a self-perpetuating cycle of redox imbalance and oxidative stress. That cycle intensified mitochondrial dysfunction and impaired the osteogenic capacity of the affected cells.

The mechanism therefore connected several elements of the stress response: acetate metabolism, acetyl-CoA abundance, protein acetylation, mitochondrial communication and the differentiation of cells that form bone. ACSS1 was identified as a key stress responder that mediated this mitonuclear communication in bone marrow skeletal stem cells. Genetic deletion of Acss1 in male mouse models of type 2 diabetes and chronic alcohol consumption restored mitochondrial resilience, osteogenic capacity and bone formation.

The researchers also used an adeno-associated virus to deliver a non-acetylatable ME2 mutant to osteoprogenitor cells; this approach produced protective effects in the models tested. Deletion of Acss1 protected against osteoporosis or osteonecrosis, while delivery of the ME2 mutant similarly counteracted the bone-forming defects associated with the experimental metabolic stresses. Because the reported experiments were conducted in mice and bone-forming cells, the results establish a mechanism in those systems rather than a clinical benefit in people.

The central finding is that nutrient stress can drive ACSS1-dependent metabolic rewiring, mitochondrial damage and impaired bone formation through a pathway involving ME2 acetylation.

Subject of Research: ACSS1-mediated metabolic stress and impaired bone formation in mouse models

Article Title: Nutrient stress-driven ACSS1 controls metabolic flexibility and bone formation

Article References: Gao, L., Yuan, Z., Huang, T., Li, P., Zhong, Y., Gao, J., Luo, Y., Li, B., Pan, H., Ye, K., & Guan, M. (2026). Nutrient stress-driven ACSS1 controls metabolic flexibility and bone formation. Nature Communications. https://doi.org/10.1038/s41467-026-77684-w

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77684-w

Keywords: ACSS1, nutrient stress, bone formation, bone marrow stem cells, mitochondrial dysfunction, osteogenesis, protein acetylation, ME2, type 2 diabetes, osteoporosis, Nutrient, stress-driven